Dr. Aggarwal’s Eye Hospital Nets Patent for Innovative Drug Delivery

The Tirunelveli branch of Dr. Agarwal’s Eye Hospital gets a patent for an innovative drug delivery technique to treat deeper corneal infections effectively. “Corneal Implants” a new innovative technique that can treat Keratitis – inflammation of the cornea caused by both bacterial and fungal damages claimed by the hospital.

Lional Raj D, regional medical director of Dr. Agarwal Eye Hospital, Tirunelveli, whose team invented the technique and stated to the reporters that Keratitis problem could lead to blindness and this technique can save the user from blindness.  He also added, according to the estimations, 30% of Keratitis cases in India leads to blindness. Fortified antibiotic eye drops are the presently available measure to treat an infectious corneal disease that requires frequent administration. Due to poor penetration of drugs by eye drops, the bioavailability of antibiotics in the deeper corneal tissues is limited.

With this innovative technique, two-three months of treatment required and varies for each individual and costs ranges from Rs 6,000 to Rs 8,000. It is free from side-effects like with the use of eye-drops. The technique first implemented and tried on Antony Raj, 45, a Tamil Nadu Generation and Distribution Corporation worker in December 2016.

Related Posts

Yashoda Medicity’s Medical Tourism Footprint widens with Republic of Kazakhstan on Board

MOU signed for Patient Referrals, Tele-Consultations and Specialist Healthcare Collaboration Delhi NCR: Unveiled not long ago, Yashoda Medcity’s reputation as being best in class healthcare facility in Delhi NCR has…

Liver enters FATal Straits in India, AIIMS Experts red flag

In first for India, World Congress of Gastroenterology comes calling to asses GI disease burden New Delhi: As global and national burden of digestive diseases reach a critical crossroads, World…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Yashoda Medicity Successfully Performs High-Risk Kidney Transplant in 28-Year- Old Woman

Yashoda Medicity Successfully Performs High-Risk Kidney Transplant in 28-Year- Old Woman

Avacta delivers two clinical stage peptide-drug conjugates to target delivery of toxic payloads into the tumour microenvironment

Avacta delivers two clinical stage peptide-drug conjugates to target delivery of toxic payloads into the tumour microenvironment

US FDA approves first gene therapy for paediatric patients with Sanfilippo syndrome type A

US FDA approves first gene therapy for paediatric patients with Sanfilippo syndrome type A

Technology and accessibility are key to growth of advanced treatment of heart diseases, says expert

Technology and accessibility are key to growth of advanced treatment of heart diseases, says expert

Puresta launches EVERQ, AI-powered skin-health platform

Puresta launches EVERQ, AI-powered skin-health platform

Stem cell therapy for autism only in approved clinical trials: Centre

Stem cell therapy for autism only in approved clinical trials: Centre